Early access
Sign in
Taking people in GermanyPhase 1

Tests how AZD6793 affects metformin in people with type 2 diabetes

Tests whether AZD6793 changes how metformin works in adults with type 2 diabetes.

Key facts

Who runs it
AstraZeneca AB
Where
Neuss, GermanySee the site
Registry title
A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus
Status
Recruiting
Phase
Phase 1
People taking part
35 people, planned
Started
1 Jul 2026
Expected to end
8 Feb 2027
Type of study
Interventional
Record updated
1 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes. It studies how the drug AZD6793 affects metformin in the body.

Age
18 years and older
Sex
All sexes can join
Disease stage
Type 2 diabetes mellitus

Where in Germany

  • PROFIL Institut fuer Stoffwechselforschung GmbHNeuss, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests how AZD6793 affects metformin in people with type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
1 July 2026